Site provided by Valneva USA, Inc.

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals.  Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

    

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals.  Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

    

 

 

REGISTER YOUR CLINIC TODAY

Exciting News for Travel Medicine Providers

As the global pandemic continues to create challenges for travel medicine providers, our team at Valneva USA has been working hard to find ways to help both you and your patients during this time of limited international travel.

Based on discussions with travel medicine specialists, we know that many clinics are focused on getting patients caught up on booster doses for relevant vaccines. To support your efforts, Valneva has launched the IXIARO® Booster Dose Program.

The IXIARO® Booster Dose Program provides a $50 patient coupon for all appropriate patients receiving a booster dose of IXIARO®.

When your clinic(s) registers for the IXIARO® Booster Dose Program:

  • Valneva will reimburse you $50 on behalf of every eligible patient, provided the patient is charged $50 less than your usual and customary charge for IXIARO®
  • Additionally, your clinic will receive a $5 administrative fee for processing each booster dose reimbursement claim*

Register for the IXIARO® Booster Dose Program Today!

To open an account for your clinic(s) please follow this easy 2-step registration process:

1. Click the link below to complete the simple clinic registration form:

2. Within 1 to 2 business days, you or your designated administrative portal user will receive a registration access link via email from noreply@ixiaroboosterprogram.com

  • Follow the link to create your account password, accept terms & conditions, and accept privacy policy†
  • Complete additional required information (eg, practitioner names and state license numbers, etc)

Once your clinic has registered, your practice will also gain access to the IXIARO® Booster Dose Program Toolkit, containing details on how to submit and track claims, and tips and promotional materials for contacting eligible patients.

Your account should be opened by the person in your office who will oversee all portal activity for your clinic(s). When registration is complete, the portal administrator will have the ability to:

  • Add participating clinics, portal users, and practitioners
  • Input and manage banking information
  • View and edit all IXIARO® Booster Dose Program patient coupon reimbursement claims within your participating clinic(s)

For more information or help with registration, please contact your Valneva representative or email IXIAROBoosterProgram@valneva.com. Please see Program Terms and Conditions for additional information.

*Patients are ineligible if their vaccine will be reimbursed in whole or in part by Medicare, Medicaid, or any other federal health care program.

†To comply with HIPAA regulations, a 2-step authentication will be required for each log-in.

Indication & Usage

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO.  Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

Valneva USA, Inc.
910 Clopper Road, Suite 160S
Gaithersburg, MD 20878, USA

Customer Service
+1 866 223 7118

Medical Information
+1 844 349 4276
     (8443-IXIARO)

This website is intended for US-based healthcare professionals.

1807-US-IX-044-1020-01  | Copyright © 2020 Valneva USA, Inc. All Rights Reserved